MML Investors Services’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.82M | Buy |
17,838
+4,911
| +38% | +$1.6M | 0.02% | 728 |
|
|
2025
Q1 | $3.49M | Buy |
12,927
+2,189
| +20% | +$591K | 0.01% | 896 |
|
|
2024
Q4 | $2.53M | Buy |
10,738
+7,652
| +248% | +$1.8M | 0.01% | 1009 |
|
|
2024
Q3 | $849K | Buy |
3,086
+166
| +6% | +$45.7K | ﹤0.01% | 1542 |
|
|
2024
Q2 | $710K | Sell |
2,920
-1,249
| -30% | -$304K | ﹤0.01% | 1588 |
|
|
2024
Q1 | $623K | Buy |
4,169
+217
| +5% | +$32.4K | ﹤0.01% | 1674 |
|
|
2023
Q4 | $756K | Buy |
3,952
+947
| +32% | +$181K | ﹤0.01% | 1519 |
|
|
2023
Q3 | $532K | Sell |
3,005
-261
| -8% | -$46.2K | ﹤0.01% | 1597 |
|
|
2023
Q2 | $620K | Buy |
3,266
+604
| +23% | +$115K | ﹤0.01% | 1499 |
|
|
2023
Q1 | $533K | Buy |
2,662
+250
| +10% | +$50.1K | ﹤0.01% | 1377 |
|
|
2022
Q4 | $573K | Buy |
2,412
+645
| +37% | +$153K | ﹤0.01% | 1438 |
|
|
2022
Q3 | $354K | Sell |
1,767
-8,148
| -82% | -$1.63M | ﹤0.01% | 1596 |
|
|
2022
Q2 | $1.45M | Buy |
9,915
+654
| +7% | +$95.4K | 0.01% | 877 |
|
|
2022
Q1 | $1.51M | Buy |
9,261
+218
| +2% | +$35.6K | 0.01% | 907 |
|
|
2021
Q4 | $1.53M | Buy |
9,043
+814
| +10% | +$138K | 0.01% | 880 |
|
|
2021
Q3 | $1.55M | Buy |
8,229
+562
| +7% | +$106K | 0.01% | 832 |
|
|
2021
Q2 | $1.3M | Buy |
7,667
+440
| +6% | +$74.6K | 0.01% | 892 |
|
|
2021
Q1 | $1.02M | Buy |
+7,227
| New | +$1.02M | 0.01% | 914 |
|